These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15012917)

  • 1. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure.
    Yamazaki T; Lee JD; Shimizu H; Uzui H; Ueda T
    Eur J Heart Fail; 2004 Jan; 6(1):41-5. PubMed ID: 15012917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.
    Tziakas DN; Chalikias GK; Papaioakeim M; Hatzinikolaou EI; Stakos DA; Tentes IK; Papanas N; Kortsaris A; Maltezos E; Hatseras DI
    Am J Cardiol; 2005 Nov; 96(10):1449-51. PubMed ID: 16275197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure.
    Banfi C; Cavalca V; Veglia F; Brioschi M; Barcella S; Mussoni L; Boccotti L; Tremoli E; Biglioli P; Agostoni P
    Eur Heart J; 2005 Mar; 26(5):481-8. PubMed ID: 15618033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators.
    Masson S; Gorini M; Salio M; Lucci D; Latini R; Maggioni AP
    Ital Heart J; 2000 Apr; 1(4):282-8. PubMed ID: 10824729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.
    Ohtsuka T; Nishimura K; Kurata A; Ogimoto A; Okayama H; Higaki J
    J Card Fail; 2007 Nov; 13(9):752-8. PubMed ID: 17996824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
    Milting H; Ellinghaus P; Seewald M; Cakar H; Bohms B; Kassner A; Körfer R; Klein M; Krahn T; Kruska L; El Banayosy A; Kramer F
    J Heart Lung Transplant; 2008 Jun; 27(6):589-96. PubMed ID: 18503956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide.
    Ho YL; Lin YH; Lee CM; Hsu RB; Ting HT; Chou NK; Chao CL; Wang SS; Hsu HC; Chen MF
    Clin Biochem; 2009 Sep; 42(13-14):1407-12. PubMed ID: 19560452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
    Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
    Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
    Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Kinoshita M
    J Card Fail; 2001 Dec; 7(4):322-8. PubMed ID: 11782855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.
    Wagner DR; Delagardelle C; Ernens I; Rouy D; Vaillant M; Beissel J
    J Card Fail; 2006 Feb; 12(1):66-72. PubMed ID: 16500583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
    Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep apnea.
    Shigemitsu M; Nishio K; Kusuyama T; Itoh S; Konno N; Katagiri T
    Int J Cardiol; 2007 Feb; 115(3):354-60. PubMed ID: 16806535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
    Mühl D; Ghosh S; Uzuelli JA; Lantos J; Tanus-Santos JE
    Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.
    Krauser DG; Lloyd-Jones DM; Chae CU; Cameron R; Anwaruddin S; Baggish AL; Chen A; Tung R; Januzzi JL
    Am Heart J; 2005 Apr; 149(4):744-50. PubMed ID: 15990762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.